IPP Bureau
ACIP votes to expand recommendation for Pfizer’s RSV vaccine ABRYSVO to include adults aged 50 – 59 at increased risk of disease
By IPP Bureau - April 17, 2025
Vote expands existing recommendation, which was for all adults aged 75 and older and high-risk adults aged 60 to 74
Abbott India elevates Anushree Kunhambu as Associate Director - New Product Introduction and Therapy Area Strategy
By IPP Bureau - April 17, 2025
Anushree has been with Abbott since 2021 and currently serving as Head of Strategy and Portfolio
Alembic announces USFDA Final Approval for Carbamazepine Tablets USP, 200 mg
By IPP Bureau - April 17, 2025
Carbamazepine Tablets USP, 200 mg have an estimated market size of US$ 32 million for twelve months ending December 2024 according to IQVIA
Lupin receives EIR from USFDA for its injectable facility in Nagpur
By IPP Bureau - April 17, 2025
The EIR was issued following an inspection of the facility conducted from June 10 to June 13, 2024
Fortis Healthcare launches Fortis Institute of Genomic Medicine
By IPP Bureau - April 17, 2025
Genomics is transforming the future of modern medicine and treatment modalities across specialties
Sigachi receives environmental clearance for greenfield Dahej manufacturing facility
By IPP Bureau - April 17, 2025
The plant will have installed production capacity of 3,120 MT/month
Aarti Pharmalabs achieves SBTi approval of GHG emission reduction targets
By IPP Bureau - April 17, 2025
Aarti Pharmalabs becomes 6th Indian Pharma/CDMO to earn SBTi approval for all 3 Scopes since 2022 demerger
Zynext Ventures invests in Feldan Therapeutics to drive innovation in intracellular drug delivery
By IPP Bureau - April 17, 2025
Feldan's proprietary Shuttle peptide technology enables the efficient and targeted delivery of biomolecules into cells, unlocking new therapeutic possibilities
AstraZeneca Pharma India surrenders marketing authorisation for Olaparib 100mg and 150mg
By IPP Bureau - April 16, 2025
The discontinuation decision is only on the basis of commercial reasons and is not due to efficacy or safety reasons
Rising Pharma gets final approval from USFDA for Mesalamine Suppositories 1000 mg
By IPP Bureau - April 16, 2025
The approved product, Mesalamine Suppositories 1000 mg, has an estimated U.S. market size of US$ 29 million
Nissan Chemical extends supply agreement with MSD Animal Health for Fluralaner
By IPP Bureau - April 16, 2025
Fluralaner invented by Nissan Chemical is the active pharmaceutical ingredient of BRAVECTO and EXZOLT,
Ami Organics to change name as Acutaas Chemicals
By IPP Bureau - April 16, 2025
This change is subject to the approval of the shareholders of the company, the Ministry of Corporate Affairs and other statutory and regulatory authorities,
Lonza joins CMAC to enhance service offering for specialty, enhanced drug product and particle technologies
By IPP Bureau - April 15, 2025
Centre for Continuous Manufacturing and Advanced Crystallisation (CMAC) aims to accelerate the digital transformation of CMC development and manufacturing approaches
Dr. Lal PathLabs becomes South Asia's first to launch advanced test for amyloidosis
By IPP Bureau - April 15, 2025
More than 40 types of Amyloid proteins are discovered till date
Biocon Biologics secures market entry date for Yesafili in US
By IPP Bureau - April 15, 2025
YESAFILI, a vascular endothelial growth factor (VEGF) inhibitor, is used to treat several different types of ophthalmology conditions
